此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

CorEvitas 全身性脓疱性银屑病 (GPP) 药物安全性和有效性登记

2026年11月4日 更新者:CorEvitas

Prospective, observational registry for subjects with GPP under the care of a dermatology investigator.Approximately 200 subjects and 75 clinical sites in North America will be recruited to participate with no defined upper limit for either target

研究概览

地位

完全的

详细说明

The objective of the registry is to obtain information on the treatment patterns, disease activity progression, and the development of comorbidities and adverse events in a cohort of patients with GPP. Data collected will be used to better characterize the natural history and longitudinal trajectory of the disease. This will be done through the standardized data collection including validated patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), the active evaluation of prevalent and incident comorbidities and adverse events, and the recording of medication utilization patterns. Personal information is also collected from each consenting registry subject allowing for linkages to other public or private clinical and administrative databases, as well as to databases maintained by organizations focused on the care and treatment of GPP for the purposes of clinical, market, or outcomes research.

This provides an opportunity to evaluate other aspects of the disease and its treatment, including but not limited to clinical and drug cost-effectiveness, health care resource utilization, and subject adherence.

研究类型

观察性的

注册 (实际的)

46

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Massachusetts
      • Waltham、Massachusetts、美国、02451
        • CorEvitas, LLC

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Subjects are enrolled in the GPP Registry during regularly scheduled office visits. Selected dermatologists are invited to participate as investigators in the Registry.

描述

Inclusion Criteria:

  • A subject must meet all the following criteria to participate in the registry:

    1. Has been diagnosed with GPP by a dermatologist or a qualified dermatology practitioner.
    2. Is at least 18 years of age and has attained the legal age for consent to procedures involved in the research, under the applicable law of the jurisdiction in which the research is being conducted.
    3. Is willing to provide consent for participation in the registry.
    4. Is willing to provide Personal Information

Exclusion Criteria:

  • Any of the following would exclude the subject from participating in the registry:

    1. Is participating or planning to participate in a blinded clinical trial evaluating a systemic agent for the treatment or prevention of flares related to GPP.
    2. Is enrolled in another CorEvitas registry for a dermatological condition. Subjects enrolled in another CorEvitas registry must be exited to be eligible for enrollment into the GPP Registry

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
Generalized Pustular Psoriasis (GPP)

Pts presenting to enrolling sites across the North America are invited to enroll if eligible

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Primary Outcome Measure:GPP epidemiology and Presentation
大体时间:Through study completion, an average of 10 years

The major clinical outcomes include an assessment of the epidemiology of GPP; to better understand the presentation and natural history.

Through study completion, an average of 10 years
GPP management, and outcomes
大体时间:Through study completion, an average of 10 years

The major clinical outcome include an assessment of the epidemiology of GPP; to better understand the management and outcomes.

Through study completion, an average of 10 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年9月19日

初级完成 (实际的)

2026年11月1日

研究完成 (实际的)

2026年11月1日

研究注册日期

首次提交

2023年10月3日

首先提交符合 QC 标准的

2023年10月23日

首次发布 (实际的)

2023年10月25日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月4日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • CorEvitas GPP-510

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅